Company intelligence / Profile preview
Foreseen Biotechnology
- Ownership
- Private
- Development stage
- Preclinical
Overview
Foreseen Biotechnology has developed a proprietary AI-powered proteomics platform to identify novel therapeutic targets. Its lead asset, FS001—an antibody-drug conjugate targeting a novel tumor-associated antigen—has demonstrated robust preclinical efficacy in multiple solid tumor models, including multidrug-resistant cancers. The company recently outlicensed global rights to FS001 to Ipsen for up to $1.03 billion; Ipsen will advance it into Phase I clinical trials[2][4][5].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateBiologic (platform focus)
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Foreseen Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Foreseen Biotechnology.